VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020.

Here is the original post:
VBL Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Novo Nordisk A/S – Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

Read the original here:
Novo Nordisk A/S – Share repurchase programme

Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

Read the rest here:
Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial

EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO …

-- Jyseleca®  Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program --Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET – Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 inhibitor for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately to, or are intolerant to, one or more disease modifying anti-rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).1

More here:
EUROPEAN  COMMISSION  GRANTS  MARKETING  AUTHORIZATION FOR JYSELECA® (FILGOTINIB)  FOR  THE  TREATMENT  OF  ADULTS  WITH  MODERATE  TO ...

Zomedica Announces Shareholder Meeting Voting Results

ANN ARBOR, Mich., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”).

See the original post here:
Zomedica Announces Shareholder Meeting Voting Results

Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with…

-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children

See the article here:
Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with...

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following virtual investor conferences in October:

View original post here:
Prevail Therapeutics to Present at Upcoming Investor Conferences

Kane Biotech Appoints New Advisor

WINNIPEG, Manitoba, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Company,” “Kane Biotech”) today announced that it has entered into an agreement with Harbor Access LLC (“Harbor Access”), an investor relations advisory firm with offices in Canada and the United States.

Read more here:
Kane Biotech Appoints New Advisor

LIDDS Announces Data on Liproca Depot from Open Label Extension Study

UPPSALA, SWEDEN – LIDDS AB (publ) announced today results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 % of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. PSA levels in the remaining six patients were in average reduced by 28 % at 2 months post treatment and reduced PSA levels remained in 2 patients at the end of the study with PSA reductions of 43 % and 73 %.

Read the original post:
LIDDS Announces Data on Liproca Depot from Open Label Extension Study

Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy

MONTREAL, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF), today announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s responsibilities include developing Medexus’ product portfolio in both the U.S. and Canada.

The rest is here:
Medexus Appoints Michael Pine as Senior Vice President of Business Development and Strategy